Supernus Pharmaceuticals (NASDAQ: SUPN), currently valued at $2.03 billion and maintaining impressive gross margins of 88.42%, is acquiring Sage Therapeutics in an all-cash transaction valued at up to ...

The research firm also expressed concerns about the deal’s long-term value, pointing out that Zurzuvae’s Orange Book-listed patents expire between 2034 and 2037, while Qelbree’s exclusivity extends ...

Another limitation highlighted in the analysis is that Supernus will not own full rights to Zurzuvae, as Sage books 50% of U.S. revenue through its co-promotion agreement with Biogen (NASDAQ: BIIB).

Six months later, Supernus got the job done with an offer of $8.50 per share, plus a contingent value right (CVR) worth $3.50 per share if a set of milestones are achieved, which would bump up the ...

Supernus will provide revised full-year 2025 financial guidance after the deal closes, it said. Shares of Cambridge, Mass.-based Sage soared 34%, to $9, in premarket trading, while shares of ...

Fewer than five months after rejecting a takeover approach by Biogen, Sage Therapeutics has found a buyer in Supernus Pharmaceuticals. According to the deal, Supernus will pay up to $795m to ...

Supernus Pharmaceuticals, Inc. SUPN on Monday agreed to acquire Sage Therapeutics, Inc. SAGE for $12.00 per share in cash, or an aggregate of up to approximately $795 million. The deal ...